Free provider profile
LAWRENCE COHEN, M.D.
NPI 1952528598
Individual
Psychiatry & Neurology, Psychiatry
Active registration
Save to rep workspaceNPI registry Registry record
Source: CMS NPPES registry, updated continuously. This record was last updated 2007-07-08.
2041 BANCROFT WAY SUITE 307-310, BERKELEY, CA, 94704
510-981-9141
Single practice location
Enumerated 2007-04-18
- — Registration is active in NPPES.
- — Individual clinician record — reachable, but usually not the buyer.
- — Practice phone number is published.
- — Full street address on file for route planning.
- — Record last updated 19 years ago.
Medicare Part D prescribing
Source: CMS Medicare Part D Prescribers by Provider, most recent public year.
Part D claims
247
Medicare patients
26
Part D drug cost
$18,757
Brand-name share
8.1%
of this prescriber's Part D claims
| Drug | Claims | Medicare cost |
|---|---|---|
| Fetzima (Levomilnacipran Hcl) | 11 | $8,710 |
| Bupropion Xl (Bupropion Hcl) | 13 | $4,520 |
| Venlafaxine Hcl Er (Venlafaxine Hcl) | 20 | $344 |
| Lithium Carbonate Er (Lithium Carbonate) | 11 | $336 |
| Dextroamphetamine-Amphetamine (Dextroamphetamine/Amphetamine) | 12 | $265 |
| Mirtazapine (Mirtazapine) | 12 | $192 |
| Clonazepam (Clonazepam) | 12 | $115 |
| Bupropion Hcl Sr (Bupropion Hcl) | 12 | $109 |
Want their full drug mix and peer benchmark? Run the free Part D prescriber lookup.
Spravato (esketamine) Medicare billing
Source: CMS Medicare Part B fee-for-service, HCPCS G2082/G2083.
202485 sessions · 19 patients · $111,764
202379 sessions · 13 patients · $98,702
Full Spravato label-compliance detail — sessions per patient against the FDA label, risk flags and year-over-year trend.
- Registry data comes straight from CMS NPPES, which lists registration, not activity — a listed practice may have moved or closed.
- Part D covers Medicare prescription drug enrollees only. Commercial, Medicaid and cash-pay prescribing is not included, so these figures are a floor on real volume, not the whole picture.
- CMS publishes the Part D file annually, roughly two years behind the prescribing year. Drugs with 10 or fewer claims are suppressed.